Among Anti‐EGFR Mabs, cetuximab (a highly studied Mab in SCC treatment) such as zalutumumab and panitumumab has shown favorable outcomes in locoregionally advanced, recurrent, or metastatic HNSCC, specifically HPV‐negative SCCs.49, 50, 53, 55, 56, 57, 58, 60, 171, 172, 173. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.